Patents by Inventor Shanthi Srinivasan

Shanthi Srinivasan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
    Patent number: 10682393
    Abstract: The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: June 16, 2020
    Assignees: Emory University, The United States Department of Veterans Affairs
    Inventor: Shanthi Srinivasan
  • Glial Cell Line Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions
    Publication number: 20180326009
    Abstract: The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 15, 2018
    Inventor: Shanthi Srinivasan
  • Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
    Patent number: 10052362
    Abstract: The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 21, 2018
    Assignees: Emory University, The United States Geovernment represented by the United States Department of Veterans Affairs
    Inventor: Shanthi Srinivasan
  • Glial Cell Line Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions
    Publication number: 20160136242
    Abstract: The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Inventor: Shanthi Srinivasan
  • Enhancing a population of insulin releasing cells using GFR ?-1 agonists
    Patent number: 9133441
    Abstract: Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-?1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 15, 2015
    Assignee: EMORY UNIVERSITY
    Inventor: Shanthi Srinivasan
  • ENHANCING A POPULATION OF INSULIN RELEASING CELLS USING GFR Alpha-1 Agonists
    Publication number: 20140186949
    Abstract: Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-?1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation.
    Type: Application
    Filed: December 17, 2013
    Publication date: July 3, 2014
    Applicant: EMORY UNIVERSITY
    Inventor: Shanthi Srinivasan
  • GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR, OBESITY, AND OBESITY-RELATED DISEASES AND CONDITIONS
    Publication number: 20140038887
    Abstract: The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof.
    Type: Application
    Filed: May 4, 2012
    Publication date: February 6, 2014
    Applicants: US GOVERNMENT REPRESENTED BY THE US DEPARTMENT OF VETERANS AFFAIRS, EMORY UNIVERSITY
    Inventor: Shanthi Srinivasan
  • Enhancing a population of insulin releasing cells using GFR-A1 agonists
    Patent number: 8637459
    Abstract: Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-?1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: January 28, 2014
    Assignee: Emory University
    Inventor: Shanthi Srinivasan
  • ENHANCING A POPULATION OF INSULIN RELEASING CELLS USING GFR-A1 AGONISTS
    Publication number: 20080187522
    Abstract: Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-?1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation.
    Type: Application
    Filed: November 7, 2007
    Publication date: August 7, 2008
    Applicant: EMORY UNIVERSITY
    Inventor: Shanthi Srinivasan